FDA关于ANDA强制降解试验的观点

Scientific Considerations of Forced degradation Studies in aNda SubmissionsaBStraCta well-designed stress study can provide insight in choos-ing the appropriate formulation for a proposed product prior to intensive formulation development studies. it can prevent re-development or re-validation of a stabil-ity indicating analytical method. this paper outlines the scientific aspects of forced degradation studies that should be considered in relation to aNda submissions. iNtroduCtioNForced degradation is synonymous with stress test-ing and purposeful degradation. Purposeful degra-dation can be a useful tool to predict the stability of a drug substance or a drug product with effects on purity, potency, and safety. it is imperative to know the impurity profile and behavior of a drug substance under various stress conditions. Forced degradation also plays an important role in the development of analytical methods, setting specifications, and design of formulations under the quality-by-design (Qbd) paradigm. the nature of the stress testing depends on the individual drug substance and the type of drug product (e.g., solid oral dosage, lyophilized powders, and liquid formulations) involved (1).the international Conference on Harmonisation (iCH) Q1B guideline provides guidance for perform-ing photostability stress testing; however, there are no additional stress study recommendations in the iCH sta-bility or validation guidelines (2). there is also limited information on the details about the study of oxidation and hydrolysis. the drug substance monographs of analytical Profiles of drug Substances and excipients provide some information with respect to different stress conditions of various drug substances (3).the forced degradation information provided in the abbreviated new drug application (aNda) submissions is often incomplete and in those cases deficiencies are cited. an overview of common deficiencies cited through-out the chemistry, manufacturing, and controls (CMC) section of the aNdas has been published (4-6). Some examples of commonly cited deficiencies related to forced degradation studies include the following:• y our d rug s ubstance d oes n ot s how a ny d egrada-tion under any of the stress conditions. Pleaserepeat stress studies to obtain adequate degra-dation. if degradation is not achievable, pleaseprovide your rationale.• P lease note that the conditions employed forstress study are too harsh and that most of yourdrug s ubstance h as d egraded. P lease r epeat y ourstress s tudies u sing m ilder c onditions o r s horterexposure t ime t o g enerate r elevant d egradationproducts.• i t is noted that you have analyzed your stressedsamples as per the assay method conditions.For the related substances method to be sta-bility indicating, the stressed samples shouldbe analyzed using related substances methodconditions.• P lease state the attempts you have made toensure that all the impurities including thedegradation p roducts o f t he u nstressed a nd t hestressed samples are captured by your analyti-cal method.ragine MaheswaranaBout tHe autHorragine Maheswaran, Ph.d., is a CMC reviewer at the office of generic drugs within the office of Pharmaceutical Science, under the uS Food and drug administration’s Center for drug evaluation and research and may be reached by e-mail at ragine.Maheswaran@.[For more author information, go to /bios• P lease provide a list summarizing the amountof d egradation p roducts (known a nd u nknown)in your stressed samples.• P lease verify the peak height requirement ofyour s oftware f or t he p eak p urity d etermination.• P lease e xplain t he m ass i mbalance o f t he s tressedsamples.• P lease identify the degradation products thatare formed due to drug-excipient interactions.• y our photostability study shows that the drugproduct is very sensitive to light. Please explainhow this is reflected in the analytical method,manufacturing process, product handling, etc.in an attempt to minimize deficiencies in the aNda submissions, some general recommendations to conduct forced degradation studies, to report relevant information in the submission, and to utilize the knowledge of forced degradation in developing stability indicating analytical methods, manufacturing process, product handling, and storage are provided in this article.StreSS CoNditioNStypical stress tests include four main degradation mecha-nisms: heat, hydrolytic, oxidative, and photolytic degrada-tion. Selecting suitable reagents such as the concentration of acid, base, or oxidizing agent and varying the conditions (e.g., temperature) and length of exposure can achieve the preferred level of degradation. over-stressing a sample may lead to the formation of secondary degradants that would not be seen in formal shelf-life stability studies and under-stressing may not serve the purpose of stress test-ing. therefore, it is necessary to control the degradation to a desired level. a generic approach for stress testing has been proposed to achieve purposeful degradation that is predictive of long-term and accelerated storage condi-tions (7). the generally recommended degradation varies between 5-20% degradation (7-10). this range covers the generally permissible 10% degradation for small molecule pharmaceutical drug products, for which the stability limit is 90%-110% of the label claim. although there are refer-ences in the literature that mention a wider recommended range (e.g., 10-30%), the more extreme stress conditions often provide data that are confounded with secondary degradation products.PhotostabilityPhotostability testing should be an integral part of stress testing, especially for photo-labile compounds. Some recommended conditions for photostability testing are described in iCH Q1B Photostability testing of New drug Substances and Products (2). Samples of drug substance, and solid/liquid drug product, should be exposed to a minimum of 1.2 million lux hours and 200 watt hours per square meter light. the same samples should be exposed to both white and uv light. to minimize the effect of temperature changes during exposure, tempera-ture control may be necessary. the light-exposed samples should be analyzed for any changes in physical proper-ties such as appearance, clarity, color of solution, and for assay and degradants. the decision tree outlined in the iCH Q1B can be used to determine the photo stability testing conditions for drug products. the product label-ing should reflect the appropriate storage conditions. it is also important to note that the labeling for generic drug products should be concordant with that of the reference listed drug (rld) and with united States Pharmacopeia (uSP) monograph recommendations, as applicable. Heatthermal stress testing (e.g., dry heat and wet heat) should be more strenuous than recommended iCH Q1a accel-erated testing conditions. Samples of solid-state drug substances and drug products should be exposed to dry and wet heat, whereas liquid drug products can be exposed to dry heat. it is recommended that the effect of temperature be studied in 10ºC increments above that for routine accelerated testing, and humidity at 75% rela-tive humidity or greater (1). Studies may be conducted at higher temperatures for a shorter period (10). testing at multiple time points could provide information on the rate of degradation and primary and secondary degrada-tion products. in the event that the stress conditions pro-duce little or no degradation due to the stability of a drug molecule, one should ensure that the stress applied is in excess of the energy applied by accelerated conditions (40º for 6 months) before terminating the stress study. acid and Base Hydrolysisacid and base hydrolytic stress testing can be carried out for drug substances and drug products in solution at ambient temperature or at elevated t emperatures. the selection of the type and concentrations of an acid or a base depends on the stability of the drug substance.a strategy for generating relevant stressed samples for hydrolysis is stated as subjecting the drug substance solution to various pHs (e.g., 2, 7, 10-12) at room tem-perature for two weeks or up to a maximum of 15% degradation (7). Hydrochloric acid or sulfuric acid (0.1 M to 1 M) for acid hydrolysis and sodium hydroxide or potassium hydroxide (0.1 M to 1 M) for base hydrolysis are suggested as suitable reagents for hydrolysis (10). For lipophilic drugs, inert co-solvents may be used tosolubilize the drug substance. attention should be given to the functional groups present in the drug molecule when selecting a co-solvent. Prior knowledge of a com-pound can be useful in selecting the stress conditions. For instance, if a compound contains ester functionality and is very labile to base hydrolysis, low concentrations of a base can be used. analysis of samples at various intervals can provide information on the progress of degradation and help to distinguish primary degradants from secondary degradants.oxidationoxidative degradation can be complex. although hydro-gen peroxide is used predominantly because it mimics possible presence of peroxides in excipients, other oxi-dizing agents such as metal ions, oxygen, and radical initiators (e.g., azobisisobutyronitrile, aiBN) can also be used. Selection of an oxidizing agent, its concentration, and conditions depends on the drug substance. Solutions of drug substances and solid/liquid drug products can be subjected to oxidative degradation. it is reported that subjecting the solutions to 0.1%-3% hydrogen peroxide at neutral pH and room temperature for seven days or up to a maximum 20% degradation could potentially generate relevant degradation products (10). Samples can be analyzed at different time intervals to determine the desired level of degradation.different stress conditions may generate the same or different degradants. the type and extent of degradation depend on the functional groups of the drug molecule and the stress conditions.aNalySiS MetHodthe preferred method of analysis for a stability indicating assay is reverse-phase high-performance liquid chroma-tography (HPlC). reverse-phase HPlC is preferred for several reasons, such as its compatibility with aqueous and organic solutions, high precision, sensitivity, and ability to detect polar compounds. Separation of peaks can be carried out by selecting appropriate column type, column temperature, and making adjustment to mobile phase pH. Poorly-retained, highly polar impurities should be resolved from the solvent front. as part of method development, a gradient elution method with varying mobile phase composition (very low organic composi-tion to high organic composition) may be carried out to capture early eluting highly polar compounds and highly retained nonpolar compounds. Stressed samples can also be screened with the gradient method to assess poten-tial elution pattern. Sample solvent and mobile phase should be selected to afford compatibility with the drug substance, potential impurities, and degradants. Stress sample preparation should mimic the sample preparation outlined in the analytical procedure as closely as possible. Neutralization or dilution of samples may be necessary for acid and base hydrolyzed samples. Chromatographic profiles of stressed samples should be compared to those of relevant blanks (containing no active) and unstressed samples to determine the origin of peaks. the blank peaks should be excluded from calculations. the amount of impurities (known and unknown) obtained under each stress condition should be provided along with the chromatograms (full scale and expanded scale show-ing all the peaks) of blanks, unstressed, and stressed samples. additionally, chiral drugs should be analyzed with chiral methods to establish stereochemical purity and stability (11, 12).the analytical method of choice should be sensitive enough to detect impurities at low levels (i.e., 0.05% of the analyte of interest or lower), and the peak responses should fall within the range of detector’s linearity. the analytical method should be capable of capturing all the impurities formed during a formal stability study at or below iCH threshold limits (13, 14). degradation product identifica-tion and characterization are to be performed based on for-mal stability results in accordance with iCH requirements. Conventional methods (e.g., column chromatography) or hyphenated techniques (e.g., lC-MS, lC-NMr) can be used in the identification and characterization of the degradation products. use of these techniques can provide better insight into the structure of the impurities that could add to the knowledge space of potential structural alerts for genotoxicity and the control of such impurities with tighter limits (12-17). it should be noted that structural characterization of degradation products is necessary for those impurities that are formed during formal shelf-life stability studies and are above the qualification threshold limit (13).various detection types can be used to analyze stressed samples such as uv and mass spectroscopy. the detec-tor should contain 3d data capabilities such as diode array detectors or mass spectrometers to be able to detect spectral non-homogeneity. diode array detection also offers the possibility of checking peak profile for multiple wavelengths. the limitation of diode array arises when the uv profiles are similar for analyte peak and impurity or degradant peak and the noise level of the system is high to mask the co-eluting impurities or degradants. Compounds of similar molecular weights and functional groups such as diastereoisomers may exhibit similar uv profiles. in such cases, attempts must be made to modify the chromatographic parameters to achieve necessaryseparation. an optimal wavelength should be selected to detect and quantitate all the potential impurities and degradants. use of more than one wavelength may be necessary, if there is no overlap in the uv profile of an analyte and impurity or degradant peaks. a valuable tool in method development is the overlay of separation signals at different wavelengths to discover dissimilarities in peak profiles.Peak Purity analysisPeak purity is used as an aid in stability indicating meth-od development. the spectral uniqueness of a compound is used to establish peak purity when co-eluting com-pounds are present.Peak purity or peak homogeneity of the peaks of interest of unstressed and stressed samples should be established using spectral information from a diode array detector. when instrument software is used for the determination of spectral purity of a peak, relevant parameters should be set up in accordance with the man-ufacturer’s guidance. attention should be given to the peak height requirement for establishing spectral purity. uv detection becomes non linear at higher absorbance values. thresholds should be set such that co-eluting peaks can be detected. optimum location of reference spectra should also be selected. the ability of the soft-ware to automatically correct spectra for continuously changing solvent background in gradient separations should be ascertained.establishing peak purity is not an absolute proof that the peak is pure and that there is no co-elution with the peak of interest. limitations to peak purity arise when co-eluting peaks are spectrally similar, or below the detec-tion limit, or a peak has no chromophore, or when they are not resolved at all.Mass BalanceMass balance establishes adequacy of a stability indicat-ing method though it is not achievable in all circum-stances. it is performed by adding the assay value and the amounts of impurities and degradants to evaluate the closeness to 100% of the initial value (unstressed assay value) with due consideration of the margin of analytical error (1).Some attempt should be made to establish a mass balance for all stressed samples. Mass imbalance should be explored and an explanation should be provided. varying responses of analyte and impurity peaks due to differences in uv absorption should also be examined by the use of external standards. Potential loss of volatile impurities, formation of non-uv absorbing compounds, formation of early eluants, and potential retention of compounds in the column should be explored. alternate detection techniques such as ri lC/MS may be employed to account for non-uv absorbing degradants. terMiNatioN oF StudyStress testing could be terminated after ensuring adequate exposure to stress conditions. typical a ctivation energy of drug substance molecules varies from 12-24 kcal/mol (18). a compound may not necessarily degrade under every single stress condition, and general guideline on exposure limit is cited in a review article (10). in cir-cumstances where some stable drugs do not show any degradation under any of the stress conditions, specificity of an analytical method can be established by spiking the drug substance or placebo with known impurities and establishing adequate separation.otHer CoNSideratioNSStress testing may not be necessary for drug substances and drug products that have pharmacopeial methods and are used within the limitations outlined in uSP <621>. in the case where a generic drug product uses a different polymorphic form from the rld, the drug substance should be subjected to stress testing to evaluate the physiochemical changes of the polymorphic form because different polymorphic forms may exhibit dif-ferent stability characteristics.ForCed degradatioNiN QBd ParadigMa systematic process of manufacturing quality drug prod-ucts that meet the predefined targets for the critical quality attributes (CQa) necessitates the use of knowledge obtained in forced degradation studies.a well-designed, forced degradation study is indis-pensable for analytical method development in a Qbd paradigm. it helps to establish the specificity of a stability indicating method and to predict potential degradation products that could form during formal stability studies. incorporating all potential impurities in the analytical method and establishing the peak purity of the peaks of interest helps to avoid unnecessary method re-development and revalidation.Knowledge of chemical behavior of drug substances under various stress conditions can also provide useful information regarding the selection of excipients for formu-lation development. excipient compatibility is an integral part of understanding potential formulation interactions during product development and is a key part of product understanding. degradation products due to drug-excipi-ent interaction or drug-drug interaction in combina-tion products can be examined by stressing samples of drug substance, drug product, and placebo separately and comparing the impurity profiles. information obtained regarding drug-related peaks and non-drug-related peaks can be used in the selection and devel-opment of more stable formulations. For instance, if a drug substance is labile to oxidation, addition of an antioxidant may be considered for the formulation. For drug substances that are labile to acid or undergo stereochemical conversion in acidic medium, delayed-release formulations may be necessary. acid/base hydrolysis testing can also provide useful insight in the formulation of drug products that are liquids or suspensions.Knowledge gained in forced degradation studies can facilitate improvements in the manufacturing process. if a photostability study shows a drug substance to be photolabile, caution should be taken during the manufacturing process of the drug product. useful information regarding process development (e.g., wet versus dry processing, temperature selection) can be obtained from thermal stress testing of drug substance and drug product.additionally, increased scientific understanding of degradation products and mechanisms may help to determine the factors that could contribute to stability failures such as ambient temperature, humidity, and light. appropriate selection of packaging materials can be made to protect against such factors. CoNCluSioNan appropriately-designed stress study meshes well with the Qbd approaches currently being promoted in the pharmaceutical industry. a well-designed stress study can provide insight in choosing the appropriate formulation for a proposed product prior to inten-sive formulation development studies. a thorough knowledge of degradation, including mechanistic understanding of potential degradation pathways, is the basis of a Qbd approach for analytical method development and is crucial in setting acceptance criteria for shelf-life monitoring. Stress testing can provide useful insight into the selection of physical form, stereochemical stability of a drug substance, packaging, and storage conditions. it is important to perform stress testing for generic drugs due to allowable qualitative and quantitative differences in formulation with respect to the rld, selection of manufacturing process, processing parameters, and packaging materials.reFereNCeS1. iCH, Q1a(r2) Stability testing of New drug Substances andProducts, geneva, February 2003.2. iCH, Q1B Stability testing: Photostability testing of New drugSubstances and Products, geneva, November 1996.3. H. Brittain, analytical Profiles of drug Substances and excipients,academic Press, london.4. a. Srinivasan and r. iser, Pharm. technol. 34(1), 50-59, 2010.5. a. Srinivasan, r. iser, and d. gill, Pharm. technol. 34(8), 45-51, 2010.6. a. Srinivasan, r. iser, and d. gill, Pharm. technol. 35(2), 58-67, 2011.7. S. Klick, et al., Pharm.technol. 29(2) 48-66, 2005.8. K. M. alsante, l. Martin and S. w. Baertschi, Pharm.technol.27(2) 60-72, 2003.9. d. w. reynolds, K. l. Facchine, J. F. Mullaney, K. M. alsante,t. d. Hatajik, and M. g. Motto, Pharm.technol. 26(2), 48-56, 2002.10. K. M. alsante, a. ando, r. Brown, J. ensing, t. d. Hatajik, w.Kong, and y. tsuda, advanced drug delivery reviews 59, 29-37 (2007).11. Fda, guidance for industry on analytical Procedures and methodsvalidation Chemistry, Manufacturing, and C ontrols documenta-tion (draft), rockville, Md, august 2000.12. iCH, Q6a: Specifications: test Procedures and acceptance Crite-ria for New drug Substances and New drug Products: Chemical Substances, geneva, october 1999.13. iCH, Q3a(r2) impurities in New drug Substances, geneva,october 2006.14. iCH, Q3B(r2) impurities in New drug Products, geneva, June2006.15. Fda, guidance for industry aNdas: impurities in drug Sub-stances (draft), rockville, Md, august 2005.16. Fda, guidance for industry aNdas: impurities in drug Products(draft), rockville, Md, November 2010.17. eMea, guideline on the limits of genotoxic impurities, Com-mittee for Medical Products for Human use (CHMP) (doc. ref eMea/CHMP/QwP/251344/2006), Jan. 1, 2007.18. K. a. Conners et al., Chemical Stability of Pharmaceuticals,wiley and Sons, New york, New york, 2nd ed., 1986) p.19.JvtaCKNowledgMeNtS aNd diSClaiMerthe author would like to thank Bob iser, Naiqi ya, dave Skanchy, Bing wu, and ashley Jung for their scientific input and support.disclaimer: the views and opinions in this articleare only those of the author and do not necessarily reflect the views or policies of the uS Food and drug administration.。

仿制药(ANDA) 申请生物等效性数据资料提交的相关指导原则（一）20090511张星一译简述：2009年4月16日，美国FDA颁布了《仿制药(ANDA) 申请生物等效性数据资料提交的相关指导原则》（Draft），规范了仿制药(ANDA) 申请提交生物等效性资料和研究数据的相关要求。

对我国的现实国情也比较有借鉴意义，故将其全文译出，以飨读者。

美国食品药品管理局（FDA ）药品审评和研究中心（CDER ）仿制药部(OGD)2009年4月该指导意见草案在最终定稿时将代表FDA就此方面的当前思想。

任何人不得以其作为权利的依据，且不能用其限制FDA和其他机构。

若所选用方法符合当前施用的法规和条例，阅读者可以采用其它方法。

若阅读者对所选方法有何建议，请与FDA相关负责人员联系。

如联络遇到问题，请拨打本文的标题页所附的电话号码。

Ⅰ前言本指导原则旨在为准备递交ANDA的申请者提供FDA有关申报生物等效性的最新要求。

FDA的最终规定-《关于提交生物等效性数据资料的要求》（BE条例），要求ANDA 申请者必须提交全部生物等效性研究数据，包括申报药物制剂的生物等效性数据和其仿制药未符合当前生物等效性评价标准2的数据。

所有相同制剂处方的生物等效性研究结果3必须以一份完整的研究报告或汇总报告的形式提交至审评部门。

修订后的条例包括对相同制剂处方的定义(§ 320.1(g))。

本指导原则提供的信息如下：·生物等效性数据条例所规定的提交ANDA资料的类型·生物等效性数据资料汇总报告的格式· FDA视为相同药物制剂的不同剂型处方组成本指导原则并未指出FDA将由制备工艺引起差异的哪些处方视为相同制剂处方。

1 该指导原则由通用名药物办公室领导的生物等效性部门制定，该部门归属于美国食品药品管理局（FDA ）药品审评和研究中心（CDER ）下属医药科学厅。

2 参见2009-1-16的联邦公报“生物等效性数据提交要求”的最终规则（生物等效性数据条例）。

FDA关于ANDA强制降解试验的观点2016-02-15HPC药闻药事风险管理谢大侠强制降解试验为方法学验证中的重要内容，为了解国外对强制降解试验的要求，根据Pharmaceutical Technology 第36卷5期中“FDA Perspectives: Scientific Considerations of Forced Degradation Studies in ANDA Submissions”一文（发布时间为2012年5月2日，作者为Ragine Maheswaran），对FDA关于强制降解试验的相关要求进行了翻译整理，具体内容如下：一、强制降解试验简介强制降解试验也称破坏性试验，其试验目的明确。

强制降解试验可预测原料药的稳定性或影响制剂的纯度、有效性和安全性的因素。

了解不同破坏条件下药物的降解产物和降解途径是非常必要的。

强制降解试验可以为分析方法的建立、说明书的制定和处方设计的确定等提供有益的参考。

样品破坏的程度取决于药物本身的性质和产品的剂型。

ICH Q1B为光稳定性试验提出了一些建议，在ICH稳定性指导原则和验证指南中，没有可以参考的关于其他降解条件的建议，对于氧化和水解降解研究也仅有有限的信息。

原料药与辅料分析方面的药物专著可以为不同原料药的各降解条件提供参考。

二、仿制药强制降解试验研究存在的问题仿制药申请时提供的强制降解试验研究数据不完整是申报的一大缺陷。

美国仿制药申报常见缺陷解读（CMC部分）已经出版，常见的一些例子说明，强制降解试验的缺陷包括以下几个方面：1.原料药在各破坏条件下均不产生降解。

请重复破坏试验以获得足够的降解产物,若没有产生降解,请提供依据。

2.破坏条件过于剧烈，导致大部分药物均被降解。

请用温和的破坏条件或减少样品暴露时间以产生相关的降解产物。

3.请注意即使你已经用含量测定的方法对破坏的样品进行了检测，为了验证有关物质的检测方法具有稳定性指示功能，破坏的样品也应用有关物质的方法进行测定。

FDA关于ANDA强制降解试验的观点：强制降解试验为方法学验证中的重要内容，为了解国外对强制降解试验的要求，根据Pharmaceutical Technology第36卷5期中“FDAPerspectives: Scientific Considerations of Forced DegradationStudies in ANDA Submissions”一文（发布时间为2012年5月2日，作者为Ragine Maheswaran），对FDA关于强制降解试验的相关要求进行了翻译整理，具体内容如下：一、强制降解试验简介强制降解试验也称破坏性试验，其试验目的明确。

强制降解试验可预测原料药的稳定性或影响制剂的纯度、有效性和安全性的因素。

了解不同破坏条件下药物的降解产物和降解途径是非常必要的。

强制降解试验可以为分析方法的建立、说明书的制定和处方设计的确定等提供有益的参考。

样品破坏的程度取决于药物本身的性质和产品的剂型。

ICHQ1B为光稳定性试验提出了一些建议，在ICH稳定性指导原则和验证指南中，没有可以参考的关于其他降解条件的建议，对于氧化和水解降解研究也仅有有限的信息。

原料药与辅料分析方面的药物专著可以为不同原料药的各降解条件提供参考。

二、仿制药强制降解试验研究存在的问题仿制药申请时提供的强制降解试验研究数据不完整是申报的一大缺陷。

美国仿制药申报常见缺陷解读（CMC部分）已经出版，常见的一些例子说明，强制降解试验的缺陷包括以下几个方面：原料药在各破坏条件下均不产生降解。

请重复破坏试验以获得足够的降解产物,若没有产生降解,请提供依据。

破坏条件过于剧烈，导致大部分药物均被降解。

请用温和的破坏条件或减少样品暴露时间以产生相关的降解产物。

请注意即使你已经用含量测定的方法对破坏的样品进行了检测，为了验证有关物质的检测方法具有稳定性指示功能，破坏的样品也应用有关物质的方法进行测定。

请提供所做的验证试验数据，以证明用以检测未破坏样品和破坏样品的方法能够检测出所有的降解杂质。

forced degradation studies破坏试验不同的研究所由不同的要求，不同的试验人员又有不同的理解，那破坏试验作为有关物质检查的一项重要试验应该怎么来做呢？化学药物由于存在未知杂质，需要进行破坏试验以确定杂质的数量，并且验证方法的可行性。

偶然翻到了一篇关于《浅谈强制降解试验》的文章，浅谈强制降解试验一文来自审评四部的黄晓龙老师，对我们的试验具有重大的指导意义。

该文简要介绍了强制降解试验的定义、目的与常规的考察项目及试验条件，为规范这方面的研究提供参考。

强制降解试验是指将原料药或制剂置于比较剧烈的试验条件下，考察其稳定性的一系列试验。

一般而言，该试验的目的主要有以下两方面：一是通过考察药品在一系列剧烈条件下的稳定性，了解该药品内在的稳定特性及其降解途径与降解产物。

例如，通过高温降解试验，可以了解所考察的药品在高温条件下是否稳定；如果不稳定，大致在何种条件下不稳定，该药品又是通过何种降解途径得到何种降解产物。

其二，这些试验也能在一定程度上对有关物质分析方法用于检查降解产物的专属性进行验证。

对于创新药，由于对其各方面的性质均不够了解，因此，通过设计比较完整的强制降解试验，可以比较全面地了解其稳定特性，从而为制剂处方、工艺的设计，以及产品储存条件的确定等提供有益的参考。

所以对于创新药而言，通过强制降解试验来了解药物的稳定特性就显得尤为重要。

对于仿制药而言，如果已有充分的文献资料对该药物的稳定特性及其降解途径与降解产物进行比较全面的阐述，则没有必要再通过强制降解试验来重复了解这些背景知识。

此时，强制降解试验的目的主要就是为了验证降解产物分析方法的专属性。

并且，由于国内在进行有关物质研究时，一般不对各有关物质进行定性研究，也无相应的杂质对照品，所以在对有关物质的分析方法进行验证时，很难用杂质对照品对方法的专属性、检测限等进行验证。

故作为对有关物质分析方法验证的一种补充，国内在制定相关指导原则时，要求对原料药及制剂进行必要的强制降解试验，以考察分析方法的可靠性。

F D A指南：A N D A原料药和制剂稳定性试验问答(201405)201405 FDA指南：ANDA：原料药和制剂稳定性试验问答Guidance for Industry 行业指南ANDAs: Stability Testing of Drug Substances and ProductsQuestions and AnswersANDA：原料药和制剂稳定性试验问答Final GUIDANCE最终稿指南U.S. Department of Health and Human ServicesFood and Drug AdministrationCenter for Drug Evaluation and Research (CDER)May 2014GenericsGuidance for IndustryANDAs: Stability Testing of Drug Substances and ProductsQuestions and AnswersANDA：原料药和制剂稳定性试验问答Additional copies are available from:Office of CommunicationsDivision of Drug Information, WO51, Room 2201 Center for Drug Evaluation and ResearchFood and Drug Administration10903 New Hampshire Ave., Silver Spring, MD 20993 Phone: 301-796-3400; Fax: 301-847-8714druginfo@U.S. Department of Health and Human ServicesFood and Drug AdministrationCenter for Drug Evaluation and Research (CDER)May 2014GenericsTABLE OF CONTENTS 目录I. INTRODUCTION介绍II. QUESTIONS AND ANSWERS提问和回答A. General一般问题B. Drug Master File药物主文件.C. Drug Product Manufacturing and Packaging药品生产和包装D. Amendments to Pending ANDA Application未批准ANDA申请的增补E. Stability Studies稳定性试验.Guidance for IndustryANDAs: Stability Testing of Drug Substances and ProductsQuestions and AnswersANDA：原料药和制剂稳定性试验问答This guidance represents the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.本指南代表的是FDA目前对这一专题的态度。

发布日期20060311栏目化药药物评价标题浅谈强制降解试验正文审评四部黄晓龙摘要：本文简要介绍了强制降解试验的定义、目的与常规的考察项目及试验条件，为规范这方面的研究提供参考。

关键词：强制降解试验目的考察项目试验条件强制降解试验是指将原料药或制剂置于比较剧烈的试验条件下，考察其稳定性的一系列试验。

一般而言，该试验的目的主要有以下两方面：一是通过考察药品在一系列剧烈条件下的稳定性，了解该药品内在的稳定特性及其降解途径与降解产物。

例如，通过高温降解试验，可以了解所考察的药品在高温条件下是否稳定；如果不稳定，大致在何种条件下不稳定，该药品又是通过何种降解途径得到何种降解产物。

其二，这些试验也能在一定程度上对有关物质分析方法用于检查降解产物的专属性进行验证。

对于创新药，由于对其各方面的性质均不够了解，因此，通过设计比较完整的强制降解试验，可以比较全面地了解其稳定特性，从而为制剂处方、工艺的设计，以及产品储存条件的确定等提供有益的参考。

所以对于创新药而言，通过强制降解试验来了解药物的稳定特性就显得尤为重要。

对于仿制药而言，如果已有充分的文献资料对该药物的稳定特性及其降解途径与降解产物进行比较全面的阐述，则没有必要再通过强制降解试验来重复了解这些背景知识。

此时，强制降解试验的目的主要就是为了验证降解产物分析方法的专属性。

并且，由于国内在进行有关物质研究时，一般不对各有关物质进行定性研究，也无相应的杂质对照品，所以在对有关物质的分析方法进行验证时，很难用杂质对照品对方法的专属性、检测限等进行验证。

故作为对有关物质分析方法验证的一种补充，国内在制定相关指导原则时，要求对原料药及制剂进行必要的强制降解试验，以考察分析方法的可靠性。

经查阅国内外相关的指导原则，均未对强制降解试验的具体项目与试验条件作明确的规定。

国内的部分研发单位在进行该项研究时，由于未充分理解该项试验的目的，所做的研究根本达不到强制降解试验的要求。

201308 FDA指南：ANDA：原料药和制剂稳定性试验问答（中英文）Guidance for Industry 行业指南ANDAs: Stability Testing of Drug Substances and ProductsQuestions and AnswersANDA：原料药和制剂稳定性试验问答DRAFT GUIDANCE指南草案This guidance document is being distributed for comment purposes only.本指南文件发布仅供讨论。

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic commentsto . Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. For questions regarding this draft document contact (CDER) Radhika Rajagopalan 240-276-8546.U.S. Department of Health and Human ServicesFood and Drug AdministrationCenter for Drug Evaluation and Research (CDER)August 2013GenericsGuidance for IndustryANDAs: Stability Testing of Drug Substances and ProductsQuestions and AnswersANDA：原料药和制剂稳定性试验问答Additional copies are available from:Office of CommunicationsDivision of Drug Information, WO51, Room 2201Center for Drug Evaluation and ResearchFood and Drug Administration10903 New Hampshire Ave., Silver Spring, MD 20993Phone: 301-796-3400; Fax: 301-847-8714druginfo@/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human ServicesFood and Drug AdministrationCenter for Drug Evaluation and Research (CDER)August 2013Generics Contains Nonbinding Recommendations Draft — Not for ImplementationTABLE OF CONTENTSI. INTRODUCTION 介绍II. QUESTIONS AND ANSWERS 问与答A. General 一般问题B. Drug Master File 药物主文件.C. Drug Product Manufacturing and Packaging 药品生产和包装D. Amendments to Pending ANDA Application 未批准ANDA申请的增补E. Stability Studies 稳定性试验.Guidance for Industry[1]ANDAs: Stability Testing of Drug Substances andProductsQuestions and AnswersANDA：原料药和制剂稳定性试验问答This draft guidance, when finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any right s for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.本指南草案，如果最终定稿，代表的是FDA目前对这一专题的态度。